The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study

Nobuko Hijiya*, Alexey Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, Terri Guinipero, Zeynep Karakas, Francisco Bautista, Stéphane Ducassou, Keon Hee Yoo, Christian Michel Zwaan, Frédéric Millot, Briana C. Patterson, Jill Samis, Miguel Izquierdo, Ksenia Titorenko, Sai Li, Darintr Sosothikul

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
10 Downloads (Pure)

Abstract

The efficacy and safety of nilotinib in pediatric patients with imatinib/dasatinib resistant/ intolerant (R/I) or newly diagnosed (ND) Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) was demonstrated in the phase 2, open-label DIALOG study. In this final analysis, long-term efficacy and safety are presented for patients who completed 66 cycles (of 28 days) of treatment with nilotinib (230 mg/m2 twice daily) or discontinued early. Overall, 59 patients were enrolled and 58 were treated (R/I, n = 33; ND, n = 25; median time on treatment: 60.5 and 51.9 months, respectively). In the R/I cohort, the cumulative major molecular response (MMR; BCR::ABL1 international scale [IS] ≤ 0.1%) rate was 60.6%, and no patients had a confirmed loss of MMR. Among ND patients, the best overall MMR rate was 76.0%; 3 patients had a confirmed loss of MMR. The cumulative molecular response MR4 (BCR::ABL1IS ≤ 0.01%) and MR4.5 (BCR::ABL1IS ≤ 0.0032%) rates by 66 cycles were 27.3% and 12.1% in the R/I cohort, and 56.0% and 44.0% in the ND cohort, respectively. The safety profile of nilotinib was consistent with those of earlier reports. No on-treatment deaths occurred. These long-term (up to ~5 years) data support the efficacy and safety of nilotinib in pediatric patients with Ph+ CML-CP. This trial was registered at www.clinicaltrials.gov.uk as #NCT01844765.

Original languageEnglish
Pages (from-to)7279-7289
Number of pages11
JournalBlood Advances
Volume7
Issue number23
DOIs
Publication statusPublished - 1 Dec 2023

Bibliographical note

Publisher Copyright:
© 2023 by The American Society of Hematology.

Fingerprint

Dive into the research topics of 'The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study'. Together they form a unique fingerprint.

Cite this